InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $2.090 0.095 (4.76%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$410 Application for quotation of securities - RAC 22 Jan 2026 3:18PM $2.740 $2.090 fallen by 23.72%
$410 Application for quotation of securities - RAC 15 Jan 2026 3:11PM $2.860 $2.090 fallen by 26.92%
$410 Racura Oncology Emory University Collaboration 14 Jan 2026 9:04AM $2.880 $2.090 fallen by 27.43%
$410 Application for quotation of securities - RAC 8 Jan 2026 2:25PM $2.820 $2.090 fallen by 25.89%
$410 Application for quotation of securities - RAC 2 Jan 2026 1:38PM $2.910 $2.090 fallen by 28.18%
$410 Racura Oncology Appoints BDD for HARNESS-1 Trial 24 Dec 2025 9:24AM $2.790 $2.090 fallen by 25.09%
$410 Application for quotation of securities - RAC 23 Dec 2025 2:13PM $2.790 $2.090 fallen by 25.09%
$410 Appendix 3Y - Dr Daniel Tillett 18 Dec 2025 4:42PM $2.540 $2.090 fallen by 17.72%
$410 Application for quotation of securities - RAC 18 Dec 2025 3:18PM $2.540 $2.090 fallen by 17.72%
$410 Cleansing Notice 11 Dec 2025 12:42PM $2.590 $2.090 fallen by 19.31%
$410 Application for quotation of securities - RAC 11 Dec 2025 12:38PM $2.590 $2.090 fallen by 19.31%
$410 Application for quotation of securities - RAC 11 Dec 2025 11:03AM $2.640 $2.090 fallen by 20.83%
$410 Change of Company Name 9 Dec 2025 4:32PM $2.780 $2.090 fallen by 24.82%
$410 Proposed issue of securities - RAC 9 Dec 2025 9:01AM $2.670 $2.090 fallen by 21.72%
$410 Race Oncology Completes $3.22m Private Placement 9 Dec 2025 8:58AM $2.670 $2.090 fallen by 21.72%
$410 Application for quotation of securities - RAC 4 Dec 2025 2:24PM $2.850 $2.090 fallen by 26.67%
$410 Appendix 3Y -Dr Peter Smith 28 Nov 2025 4:19PM $2.850 $2.090 fallen by 26.67%
$410 Appendix 3Y - Dr Daniel Tillett 28 Nov 2025 4:18PM $2.850 $2.090 fallen by 26.67%
$410 Application for quotation of securities - RAC 27 Nov 2025 1:22PM $2.810 $2.090 fallen by 25.62%
$410 Race Oncology AGM 2025 Recording Released 27 Nov 2025 12:59PM $2.790 $2.090 fallen by 25.09%
$410 Race Receives $2.8m RD Tax Refund 27 Nov 2025 8:59AM $2.900 $2.090 fallen by 27.93%
$410 HARNESS1 Lung Cancer Trial Receives Human Ethics Approval 26 Nov 2025 9:29AM $2.910 $2.090 fallen by 28.18%
$410 Replacement Appendix 3Y - Dr Daniel Tillett 25 Nov 2025 5:56PM $2.910 $2.090 fallen by 28.18%
$410 Appendix 3Y - Dr Serge Scrofani 25 Nov 2025 4:54PM $2.910 $2.090 fallen by 28.18%
$410 Appendix 3Y - Dr Megan Baldwin 25 Nov 2025 4:53PM $2.910 $2.090 fallen by 28.18%

76 - 100 of 988 results

Page 4 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.